A detailed history of Balasa Dinverno & Foltz LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Balasa Dinverno & Foltz LLC holds 4,029 shares of VRTX stock, worth $1.64 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
4,029
Previous 1,931 108.65%
Holding current value
$1.64 Million
Previous $544,000 114.52%
% of portfolio
0.07%
Previous 0.03%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 25, 2022

BUY
$273.83 - $305.53 $574,495 - $641,001
2,098 Added 108.65%
4,029 $1.17 Million
Q2 2022

Aug 09, 2022

BUY
$234.96 - $292.55 $453,707 - $564,914
1,931 New
1,931 $544,000
Q1 2021

Apr 29, 2021

SELL
$207.02 - $241.31 $203,707 - $237,449
-984 Closed
0 $0
Q4 2020

Jan 26, 2021

SELL
$207.01 - $276.09 $314,448 - $419,380
-1,519 Reduced 60.69%
984 $233,000
Q3 2020

Nov 10, 2020

SELL
$255.65 - $303.1 $194,805 - $230,962
-762 Reduced 23.34%
2,503 $681,000
Q2 2020

Aug 07, 2020

BUY
$225.48 - $295.8 $370,463 - $485,999
1,643 Added 101.29%
3,265 $948,000
Q1 2020

Apr 30, 2020

BUY
$199.77 - $247.81 $324,026 - $401,947
1,622 New
1,622 $386,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Balasa Dinverno & Foltz LLC Portfolio

Follow Balasa Dinverno & Foltz LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balasa Dinverno & Foltz LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balasa Dinverno & Foltz LLC with notifications on news.